{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["60(12)"],"submitter":["Kobayashi S"],"pubmed_abstract":["<h4>Background</h4>Systemic chemotherapy with gemcitabine plus S-1 (GEM + S-1), GEM + CDDP plus S-1 (GEM + CDDP + S-1), or gemcitabine plus cisplatin (GEM + CDDP) is standard treatment for advanced biliary tract cancer (aBTC). We aimed to evaluate the efficacy and safety of combination chemotherapy in older patients with aBTC.<h4>Methods</h4>This multicenter prospective observational study (JON2104-B, UMIN000045156) included patients aged ≥ 70 years with aBTC. Inverse-probability weighting propensity-score analyses (IPW) were used to compare overall survival (OS) as the primary endpoint and progression-free survival (PFS) across treatment groups.<h4>Results</h4>This study included 305 patients between August 2021 and January 2023. Of them, 75, 131, 26, 52, and 10 received GEM + CDDP + S-1,"],"journal":["Journal of gastroenterology"],"pagination":["1584-1595"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12630146"],"repository":["biostudies-literature"],"pubmed_title":["Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B)."],"pmcid":["PMC12630146"],"pubmed_authors":["Shioji K","Nebiki H","Okuyama H","Ashida R","Kobayashi S","Shimizu S","Arima S","Ikezawa K","Tsuji K","Kobayashi N","Tsumura H","Shibuki T","Ueno M","Terashima T","Satoh T","Furuse J","Naganuma A","Nakachi K","Oshima K","Ohno I","Doi T","Tsuchiya K","Yamamoto K","Komatsu Y","Masaki Y","Kita E","Unno M","Okamura Y","Asagi A","Maruki Y","Kataoka S","Negoro Y","Sakamoto Y","Itoi T","Nagano H","Umemoto K","Asama H","Kojima Y","Matsumoto K","Okano N","Ozaka M"],"additional_accession":[]},"is_claimable":false,"name":"Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B).","description":"<h4>Background</h4>Systemic chemotherapy with gemcitabine plus S-1 (GEM + S-1), GEM + CDDP plus S-1 (GEM + CDDP + S-1), or gemcitabine plus cisplatin (GEM + CDDP) is standard treatment for advanced biliary tract cancer (aBTC). We aimed to evaluate the efficacy and safety of combination chemotherapy in older patients with aBTC.<h4>Methods</h4>This multicenter prospective observational study (JON2104-B, UMIN000045156) included patients aged ≥ 70 years with aBTC. Inverse-probability weighting propensity-score analyses (IPW) were used to compare overall survival (OS) as the primary endpoint and progression-free survival (PFS) across treatment groups.<h4>Results</h4>This study included 305 patients between August 2021 and January 2023. Of them, 75, 131, 26, 52, and 10 received GEM + CDDP + S-1,","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-05T17:34:10.156Z","creation":"2026-05-19T03:11:55.267Z"},"accession":"S-EPMC12630146","cross_references":{"pubmed":["40913639"],"doi":["10.1007/s00535-025-02294-0"]}}